Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
  • ltxrtquq@lemmy.mlEnglish
    14·
    28 天前

    DiMarchi and Tschöp’s pioneering work on the study of GLP-1 hormones contributed to the foundation for popular weight-management drugs sold under name brands like Zepbound and Wegovy. They discovered that the weight-loss effects from therapeutics containing the GLP-1 hormone activity could be enhanced by including two other hormone activities: glucagon and GIP.

    Not this time, right now we’re talking about other drugs that can be used for weight loss.